Lonza, a supplier to the pharmaceutical, biotech and specialty ingredients markets, has entered into drug product services to offer customers a complete portfolio of development and manufacturing services for clinical outsourcing requirements.
This new service offering is part of Lonza’s drive to enable customers to meet some of the greatest challenges in patient treatment. These drug product services will focus on parenteral dosage forms, including products for injection and infusion for intravenous, subcutaneous, intraocular and other routes of parenteral administration. Services will include options for monoclonal antibodies, other biologics, drug conjugates, peptides and small molecules that require a parenteral dosage form.
Drug product services will be offered in the fourth quarter of 2016 from laboratories based in Basel (Switzerland), with an initial focus on formulation development and drug product analytical development and quality control. Specialised services will also be available for customers, such as particulate identification, characterisation and quantification, excipient and surfactant characterisation, extractables & leachables assessment and testing of container closure integrity. Drug product manufacturing capabilities for preclinical and clinical use (cGMP) will be available in late 2016.
“Expansion of our portfolio into drug product services fits well with our existing and future customers’ needs and is an important step in becoming a one-stop-shop for all clinical outsourcing requirements,” said Marc Funk, COO of Lonza.
